AMBI Key Stats
|Revenue (Quarterly YoY Growth)||79.31%|
|EPS Diluted (TTM)||-1.908|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-14.16M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-79.04%|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI PR Newswire Dec 5
- Buy The Fear With Ambit Biosciences Dec 5
- AMBI Plunges on Disappointing FDA News Dec 5
- Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference noodls Dec 5
- AMBI Plunges on Disappointing FDA News - Analyst Blog Zacks Dec 5
- Why Express, Ambit Biosciences, and Thompson Creek Metals Tumbled Today Fool Dec 4
- Ambit Biosciences (AMBI) Defended at Citi Street Insider Dec 4
- Why Ambit Biosciences Corp. Shares Were Crushed Fool Dec 4
- Unusual 11 Mid-Day Movers 12/04: (OCLS) (ABIO) (TNXP) Higher; (AMBI) (TRQ) (EXPR) Lower Street Insider Dec 4
- BMO Capital Downgrades Ambit Biosciences (AMBI) to Market Perform Street Insider Dec 4
AMBI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Ambit Biosciences is up N/A over the last year vs S&P 500 Total Return up 30.90%, Actelion up 65.42%, and Vanda Pharmaceuticals up 214.4%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for AMBI
Pro Strategies Featuring AMBI
Did Ambit Biosciences make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Ambit Biosciences Corp is a biotechnology company engaged in discovering, developing & commercializing small molecule therapeutics for the treatment of cancer. It is developing drug candidate, quizartinib, for the treatment of acute myeloid leukemia.